<DOC>
	<DOCNO>NCT00002010</DOCNO>
	<brief_summary>The study intend examine efficacy fluconazole treatment coccidioidal meningitis patient new onset infection , relapse previous infection , fail previous therapy . Drug efficacy , safety tolerance examine .</brief_summary>
	<brief_title>Open , Non-Comparative Study Fluconazole Patients With Coccidioidal Meningitis</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Immunosuppressive therapy include corticosteroid and/or cytotoxic agent . Antiviral therapy ( e.g. , zidovudine ( AZT ) ) . Prophylaxis Pneumocystis carinii pneumonia ( PCP ) . Any exception use concomitant medication must approve Pfizer Central Research prior study entry . Concurrent Treatment : Allowed : Radiation therapy mucocutaneous Kaposi 's sarcoma . Patients must : Be clinically judged need treatment coccidioidal meningitis . Have &gt; 1 week life expectancy . Allowed : Immunocompromised patient . Patients renal disease dose fluconazole adjust serum level may monitor . Prior Medication : Allowed : Amphotericin B. Ketoconazole . Miconazole . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Current antifungal infection respond another agent . Findings improvement include one following , therapy ( without subsequent relapse item ) : CSF culture conversion positive negative . OR CSF antibody titer decrease least one dilution . OR Improvement sign symptom meningitis . Have receive minimal systemic antifungal therapy ( see Patient Inclusion Criteria ) , unless meet criterion previous treatment failure relapse . They must receive therapy since time relapse failure document , except minimal antifungal therapy allow Patient Inclusion Criteria . Immediately lifethreatening coccidioidomycosis define infection degree clinical severity patient would expect die within 1 week , untreated , base clinical judgment . Experienced prior allergic reaction major side effect imidazole triazole compound . Concurrent Medication : Excluded : Barbiturates . Phenytoin . Oral hypoglycemics . Coumadin type anticoagulant . Other systemic intrathecal antifungal therapy . Other experimental agent exception note concomitant medication section . Any exception prohibition concomitant medication must approve Pfizer Central Research prior study entry . Patients follow exclude : Are respond improve current antifungal therapy another agent . Have receive minimal systemic antifungal therapy ( see Patient Inclusion Criteria ) , unless meet criterion previous treatment failure relapse . They must receive therapy since time relapse failure document , except minimal antifungal therapy allow Patient Inclusion Criteria . Immediately lifethreatening coccidioidomycosis define infection degree clinical severity patient would expect die within 1 week , untreated , base clinical judgment . Experienced prior allergic reaction major side effect imidazole triazole compound .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1992</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Coccidioidin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Coccidioidomycosis</keyword>
</DOC>